Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Xing Fan, Lipeng Xu, Jianhao Zhang, Yidan Wang, Zirui Wu, Wenjing Sun, Xin Yao, Xu Wang, Shanshan Guan, Yaming ShanInternational Journal of Molecular Sciences 2023 · DOI

TL;DR

This study explores the potential of single-chain variable fragments (scFvs) as a novel therapeutic approach for Alzheimer's disease (AD). Researchers designed and characterized scFvs mimicking known therapeutic antibodies, finding that one scFv (scFv-C) effectively disaggregates amyloid-beta 42 (Aβ42) fibers and inhibits further aggregation, suggesting its promise for AD treatment.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques in the brain. Aβ42, a specific form of Aβ, is particularly implicated in synaptic damage and neuronal death, making it a prime target for therapeutic intervention. While monoclonal antibodies (mAbs) have shown promise in targeting Aβ, they can have limitations such as side effects and difficulty crossing the blood-brain barrier. This paper addresses the need for more effective and potentially safer AD therapeutics by investigating the use of single-chain variable fragments (scFvs) – smaller antibody fragments that may offer improved penetration and reduced immunogenicity. Specifically, the study aims to design, construct, and evaluate scFvs based on existing therapeutic mAbs to understand their mechanism of action in disaggregating Aβ42.

Methods

The researchers employed a multi-pronged approach:

  • scFv Design and Construction: They designed scFvs (scFv-C, scFv-S, and scFv-12B4) based on the antigen-binding sequences of three known anti-Aβ mAbs: Crenezumab, Solanezumab, and 12B4. These scFvs were then constructed and expressed in E. coli.
  • Characterization of scFvs:
    • Western Blotting: Used to confirm the successful expression and purity of the synthesized scFvs.
  • ELISA (Enzyme-Linked Immunosorbent Assay): Employed to assess the binding affinity of the scFvs to Aβ42, quantifying their dissociation constants (Kd).
  • Thermal Stability Analysis (Nano Temper Tycho): Evaluated the thermal stability of the scFvs by monitoring their unfolding profiles, which is crucial for maintaining function under physiological conditions.
  • Thioflavin-T (THT) Assay: Used to measure the depolymerization of aggregated Aβ42 fibers by the scFvs, indicated by a decrease in fluorescence intensity.
  • Molecular Dynamics (MD) Simulations: To delve deeper into the mechanism of interaction between the most promising scFv (scFv-C) and Aβ42, MD simulations were performed. This involved:
  • 3D Structure Construction: Building the 3D structures of scFv-C and an Aβ42 pentamer (Aβ5) complex using homology modeling and docking.
  • MD Simulation: Simulating the dynamic behavior of the scFv-C-Aβ5 complex and individual Aβ5 over 200 ns to observe structural changes and interactions.
  • Binding Energy Calculation (MM/PBSA): Estimating the binding free energy between scFv-C and Aβ5 to identify key residues involved in the interaction.
  • Structural Analysis (RMSD and Secondary Structure): Analyzing root-mean-square deviation (RMSD) and secondary structure changes to quantify structural perturbation and understand how scFv-C affects Aβ5 conformation.

Datasets

Not discussed in the paper. The study primarily relies on in vitro experiments and computational simulations rather than large-scale datasets.

Key Insights and Ideas

  • scFvs as viable AD therapeutics: The study successfully demonstrates that scFvs can be engineered to mimic the therapeutic functions of larger mAbs, offering a potentially advantageous alternative.
  • scFv-C's superior binding and disaggregation: Among the tested scFvs, scFv-C exhibited significantly higher binding affinity to Aβ42 and a remarkable ability to depolymerize pre-formed Aβ42 fibers. This suggests a specific mechanism of action that is more potent than the other tested scFvs.
  • Mechanism of disaggregation: MD simulations revealed that scFv-C interacts with Aβ42 through hydrogen bonds and salt bonds. Crucially, the simulations showed that scFv-C binding leads to structural disturbances in the Aβ42 pentamer, particularly in the Ala21-Gly29 region, suggesting that scFv-C can disrupt the fiber structure and potentially inhibit further aggregation.
  • Thermal stability is key: The scFvs demonstrated good thermal stability, indicating they can maintain their structure and function under physiological conditions, a critical factor for therapeutic efficacy.

Key Results

  • Binding Affinity: scFv-C showed a significantly better binding ability to Aβ42 than scFv-S and scFv-12B4, with a dissociation constant (Kd) of approximately 2.0 × 10⁻⁹ M for Aβ42.
  • Depolymerization of Aβ42: After 23 hours of incubation, scFv-C reduced the fluorescence intensity of aggregated Aβ42 to 39%, indicating effective depolymerization.
  • Thermal Stability: The scFvs exhibited good thermal stability, with inflection temperatures (Ti) suggesting they remain relatively stable in the range of human body temperature.
  • MD Simulation Insights: Molecular dynamics simulations predicted interactions between scFv-C and Aβ42 pentamers via hydrogen and salt bonds. Analysis of RMSD and secondary structure changes indicated that scFv-C binding perturbs the structure of Aβ42, suggesting a mechanism for disaggregation and inhibition of further aggregation.

Limitations and Future Work

  • Limitations:
    • The study was conducted in vitro and using computational models. The efficacy and safety of scFv-C in a living organism (e.g., animal models) have not yet been demonstrated.
  • While scFvs are generally considered safer than mAbs, potential immunogenicity or off-target effects in vivo remain to be investigated.
  • The study focused on Aβ42; the effectiveness against other Aβ species or in the complex environment of the AD brain needs further exploration.
  • Future Work:
    • The authors suggest that scFv-C could be employed to treat AD model mice of different ages to explore its effects on the nervous system.
  • Further experiments are needed to fully elucidate the therapeutic potential and safety profile of scFv-C for clinical application in AD.

Summary updated

Abstract

Alzheimer's disease (AD) is a specific neurodegenerative disease. This study adopts single-chain variable fragments (scFvs) as a potential immunotherapeutic precursor for AD. According to the remarkable effects of monoclonal antibodies, such as the depolymerization or promotion of Aβ42 efflux by Crenezumab, Solanezumab, and 12B4, it is attractive to prepare corresponding scFvs targeting amyloid-β-42 protein (Aβ42) and investigate their biological activities. Crenezumab-like scFv (scFv-C), Solanezumab-like scFv (scFv-S), and 12B4-like scFv (scFv-12B4) were designed and constructed. The thermal stabilities and binding ability to Aβ42 of scFv-C, scFv-S, and scFv-12B4 were evaluated using unfolding profile and enzyme-linked immunosorbent assay. As the results indicated that scFv-C could recognize Aβ42 monomer/oligomer and promote the disaggregation of Aβ42 fiber as determined by the Thioflavin-T assay, the potential mechanism of its interaction with Aβ42 was investigated using molecular dynamics analysis. Interactions involving hydrogen bonds and salt bonds were predicted between scFv-C and Aβ42 pentamer, suggesting the possibility of inhibiting further aggregation of Aβ42. The successfully prepared scFvs, especially scFv-C, with favorable biological activity targeting Aβ42, might be developed for a potentially efficacious clinical application for AD.
BibTeX
@article{fan2023mechanism,
  author = {Xing Fan and Lipeng Xu and Jianhao Zhang and Yidan Wang and Zirui Wu and Wenjing Sun and Xin Yao and Xu Wang and Shanshan Guan and Yaming Shan},
  title = {{Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies}},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24098371},
}
Figure